



Dr. med. Aurelius Omlin

Medizinische Onkologie und Hämatologie · Dept. I

Kontakt

Dr. med. Aurelius Omlin
Rorschacherstrasse 95
9007 St.Gallen
Switzerland

T 071 494 11 11
aurelius.omlin@kssg.ch

Bereiche

Medizinische Onkologie und Hämatologie

Publikationen (106)

Koster K, Zumstein V, Süveg K, Jochum W, Husarik D, Omlin A. Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer. *BJU Int* 2022

Koster K, Rothermundt C, Binet I, Borovicka J, Clerici T, Engeler D, Greiner J, Hader C, Azzarello-Burri S, Lang C, Omlin A, Krull I, Stöckli S, Hundsberger T. Von-Hippel-Lindau-Erkrankung - Interdisziplinäre Betreuung und neue therapeutische Optionen. *Schweiz Aerztezeitung* 2022; 48:4-784-787.

Mucci L, Vinson J, Gold T, Gerke T, Filipenko J, Green R, Anderson S, Badal S, Bjartell A, Chi K, Davis I, Enting D, Fay A, Lazarus J, Mateo J, McDermott R, Odedina F, Olmos D, Omlin A, Popoola A, Ragin C, Roberts R, Russnes K, Waihenya C, Stopsack K, Hyslop T, Villanti P, Kantoff P, George D. IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer. *JCO Glob Oncol* 2022; 8:e2200154.

Fischer S, Götze T, Omlin A, Baird R, Dawson K, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C. A Case of Sustained Tumor Regression With MP0274, a Novel DARPIn Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. *JCO Precis Oncol* 2022; 6:e2200006.

Aeppli S, Engeler D, Fischer S, Omlin A, Pratsinis M, Hermann C, Rothermundt C. Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018. *Swiss Med Wkly* 2022; 152:w30175.

Omlin A, Nestor K. Navigating Difficult Waters: A Cancer Journey. *J Clin Oncol* 2022; 40:911-914.

Vogl U, Mottet N, Padhani A, Roach M, Rubin M, Sartor O, Small E, Smith M, Soule H, Sydes M, Tombal B, Omlin A, Gillessen S, James N, Halabi S, Beer T, Davis I, Shore N, Sweeney C, Ost P, Attard G, Bossi A, de Bono J, Drake C, Efsthathiou E, Fanti S, Fizazi K, APCCC 2019 expert panel. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. *Eur J Cancer* 2021; 160:24-60.

Achard V, Putora P, Omlin A, Zilli T, Fischer S. Metastatic Prostate Cancer: Treatment Options. *Oncology* 2021; 100:48-59.

Beyer J, Stenner F, Spahn M, Seiler R, Rothermundt C, Roth B, Papachristofilou A, Omlin A, Lorch A, Honecker F, Hermanns T, Gross T, Gillessen S, Fischer S, Fankhauser C, Cathomas R, Bode P, Berthold D, Bührer E. Swiss germ-cell cancer consensus recommendations. *Swiss Med Wkly* 2021; 151

Pratsinis M, Halabi S, Güsewell S, Gillessen S, Omlin A. In-depth analysis of the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) - The importance of representation of medical specialty and geographic regions. *Eur Urol Open Sci* 2021; 26:14-17.

Baird R, Fischer S, Azaro A, Harstrick A, Stumpp M, Leupin N, Dawson K, Fiedler U, Zitt C, Rodón J, Harris A, Lord S, Middleton M, Linossi C, Omlin A. First-in-Human Phase I Study of MP0250, a First-in-Class DARPIn Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. *J Clin Oncol* 2020; 39:145-154.

Schmid S, De Giorgi U, Hansen A, Beer T, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman A, Le M, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Bianchini D, Chi K, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen M, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh W, Tsao C, Sartor O, Ledet E, Di Lorenzo G, Yip S, Gillessen S. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. *JAMA Netw Open* 2020; 3:e2021692.

Mukherji D, Omlin A, Pezaro C. Living Longer and Better with Advanced Prostate Cancer. *Eur Urol* 2020; 78:358-359.

STAMPEDE Investigators, Parikh O, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N, James N, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Brown J, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: *Ann Oncol* 2019; 30: 1992-2003. *Ann Oncol* 2020; 31:442.

Omlin A, Ryan C, Rubin M, Roach M, Reiter R, Pritchard C, Poon D, Parker C, Padhani A, O'Sullivan J, Ost P, Oh W, Murthy V, Murphy D, Mrabti H, Mottet N, Morris M, Saad F, Sade J, Zapatero A, van Oort I, Türkeri L, Tombal B, Taplin M, Sydes M, Sweeney C, Suzuki H, Steuber T, Sternberg C, Soule H, Smith M, Small E, Shore N, Scher H, Sartor O, Morgans A, Millman R, Evans C, Efstathiou E, Eeles R, Duran I, Drake C, de Bono J, Davis I, Clarke N, Chi K, Bristow R, Briganti A, Bossi A, Bjartell A, Beltran H, Beer T, Attard G, Fanti S, Feng F, Maluf F, Logothetis C, Leibowitz R, Khauli R, Kantoff P, Kanesvaran R, James N, Hussain M, Hofman M, Higano C, Heinrich D, Heidenreich A, Halabi S, Gleave M, Frydenberg M, Fizazi K, Gillessen S. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *Eur Urol* 2020; 77:508-547.

Aeppli S, Sternberg C, Schmidinger M, Rini B, Porta C, Omlin A, Oldenburg J, McDermott D, Gruenwald V, Larkin J, Fischer S, Escudier B, Eisen T, Eboulet E, Rothermundt C. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. *ESMO Open* 2020; 5

Schmid S, Omlin A. Progress in therapy across the spectrum of advanced prostate cancer. *Nat Rev Urol* 2019

Ferraro D, Hermanns T, Kaufmann P, Omlin A, Kranzbühler H, Gablinger R, Müller A, Müller J, Eberli D, Muehlematter U, Garcia Schüller H, Burger I. Impact of Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. *Eur J Nucl Med Mol Imaging* 2019

Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol* 2019; 30:e3.

Antonarakis E, Procopio G, Fukasawa S, Tabata K, Park S, Feyerabend S, Drake C, Wu H, Qiu P, Kim J, Poehlein C, Omlin A, Li C, Piulats J, Gross-Goupil M, Goh J, Ojamaa K, Hoimes C, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, de Bono J. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. *J Clin Oncol* 2019;JCO1901638.

James N, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Brown J, Parikh O, Protheroe A, Rudman S, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Srihari N, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. *Ann Oncol* 2019

Rescigno P, Romero-Laorden N, Castro E, Saez M, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu S, Sternberg C, De Giorgi U, Olmos D, Morley C, Pezaro C, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin A, Schmid S, Caffo O, Zivi A, de Bono J. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. *Eur Urol Oncol* 2019

Mukherji D, Hussain H, Sayyid K, Ibrahim K, Haidar M, Zouain N, Bitar N, Alameh W, Abbas F, Faddoul S, Nemer E, Assaf G, Farhat F, Bulbul M, Temraz S, Shamseddine A, Gillessen Sommer S, Omlin A, Sakr G, El Khoury C, Youssef B, Dagher C, El-Hajj A, Nasr R, Geara F, Rabah D, Al Dousari S, Said R, Ashou R, Wazzan W, Jabbour M, Farha G, Al Hamdani N, Al Hallaq Y, Ghazal H, Dbouk H, Bachir B, Khauli R. Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations. *World J Urol* 2019

Pérez-López R, de Bono J, Morris M, Omlin A, Vargas H, Fanti S, Oyen W, Padhani A, Tunariu N, Koh D. Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. *Radiology* 2019; 292:273-286.

Betschart P, Schmid H, Klingbiel D, Engeler D, Gillessen Sommer S, Schwab C, Abt D, Rothermundt C, Schmid S, Babst C, Omlin A. Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model. *Oncol Res Treat* 2019; 42:366-374.

Omlin A, Gillessen Sommer S. The Advanced Prostate Cancer Consensus on a regional level - what can we learn?. *BJU Int* 2019; 123:3-4.

Betschart P, Omlin A, Abt D. Seminal vesicle sparing robotic radical prostatectomy - no different interpretation of postoperative PSA follow-up required?. *Swiss Med Wkly* 2018; 148:w14698.

Müller J, von Schulthess G, Kaufmann P, Kranzbuehler H, John H, Zilli T, Müller A, Omlin A, Schmid D, Sulser T, Kroeze S, Guckenberger M, Eberli D, Kedzia S, Garcia Schüller H, Muehlemaier U, Ferraro D, Burger I. Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. *Eur J Nucl Med Mol Imaging* 2018

Omlin A, Zwahlen D, Wyler S, Wild D, Templeton A, Stenner F, Schmid H, Roggero E, Rentsch C, Nitzsche E, Kueng M, Jochum W, Gillessen Sommer S, Eberli D, Beyer J, Spahn M, Cathomas R. [Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]. *Praxis (Bern 1994)* 2018; 107:1043-1051.

Sajic T, Claassen M, Gillessen Sommer S, Omlin A, Malander S, Niméus E, Friedrich B, Blattmann P, Chen R, Brentnall T, Pan S, Sethi A, Hüttenhain R, Schiess R, Williams E, Surinova S, Arvaniti E, Liu Y, Aebbersold R. Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS. *Cell Rep* 2018; 23:2819-2831.e5.

Sumanasuriya S, Luo J, Mehra N, Olmos D, Scher H, Soule H, Stoecklein N, Terstappen L, Waugh D, Lorente D, Lolkema M, Omlin A, Armstrong A, Attard G, Chi K, Bevan C, Shibakawa A, IJzerman M, De Laere B, de Bono J. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. *Eur Urol Oncol* 2018; 1:151-159.

Gong J, Omlin A, Pal S, Hsu J, Tombal B, Sydes M, Gillessen Sommer S. Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer. *Eur Urol* 2018

Isensee G, Péporté A, Müller J, Schmid S, Gillessen Sommer S, Omlin A. Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?. *Clin Genitourin Cancer* 2018; 16:349-354.

Gordon J, Cox M, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl B, Cherhroudi C, Pignata S, Battaglia M, Buonerba C, Pond G, Crona D, Gillessen Sommer S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke J, Bosso D, Milowsky M, Witek M, Di Lorenzo G. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. *Oncotarget* 2018; 9:19861-19873.

Omlin A, Gillessen Sommer S. When and how to use carboplatin in metastatic castration-resistant prostate cancer?. *Eur J Cancer* 2018; 92:96-99.

Viktorin P, Omlin A, Schmid H. Prostatakarzinom im Alter. Diagnostik und Therapie bei Betagten. *info@onkologie* 2018; 8:5-8.

Omlin A, Zwahlen D, Wyler S, Wild D, Templeton A, Stenner F, Schmid H, Roggero E, Rentsch C, Nitzsche E, Kueng M, Jochum W, Gillessen Sommer S, Eberli D, Beyer J, Spahn M, Cathomas R. Behandlung des fortgeschrittenen Prostatakarzinoms - eine interdisziplinäre Empfehlung. *Schweiz Rundschau Med (PRAXIS)* 2018; 107:1043-51.

Fankhauser C, Moch H, Sulser T, Poyet C, Hermanns T, Rueschoff J, Rupp N, Omlin A, Gillessen Sommer S, Schöffler P, Wild P. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. *Oncotarget* 2017; 9:10284-10293.

Heinrich D, van Oort I, Tucci M, Sridhar S, Omlin A, Olmos D, Kramer G, Kindblom J, Keizman D, Daugaard G, Chi K, Cathomas R, Caffo O, Bergman A, Bektic J, Nilsson S. The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. *Clin Genitourin Cancer* 2017

Gillessen Sommer S, de Bono J, Sartor O, Omlin A. Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *Eur Urol*. In press. <http://dx.doi.org/10.1016/j.eururo.2017.06.002>. *Eur Urol* 2017

Endt K, Joos T, Gillessen Sommer S, Steuber T, Engeler D, Rainisio M, Guenther A, Tennstedt P, Athanasiou A, Omlin A, Goepfert J, Schiess R. Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. *PloS one* 2017; 12:e0181557.

Pezaro C, James N, Logothetis C, Morgans A, Parker C, Ryan C, Saad F, Sartor O, Small E, Sternberg C, Sweeney C, Tannock I, Tombal B, Hussain M, Higano C, Omlin A, Mastris K, Attard G, Beer T, Chi K, Chowdhury S, Davis I, Drake C, de Bono J, Efstathiou E, Gravis G, Gillessen Sommer S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. *Ann Oncol* 2017; 28:1692-1694.

Omlin A, Ryan C, Rubin M, Roach M, Pritchard C, Parker C, Padhani A, Ost P, Oh W, Murthy V, Mottet N, Morris M, Morgans A, Maluf F, Saad F, Sartor O, Wiegel T, Valdagni R, Tombal B, Tannock I, Sydes M, Sweeney C, Suzuki H, Sternberg C, Soule H, Smith M, Shore N, Sella A, Scher H, Logothetis C, Kramer G, Khauli R, Dos Reis R, de Bono J, Davis I, Daugaard G, Clarke N, Chung B, Castellano D, Carver B, Bristow R, Bossi A, Beltran H, Beer T, Attard G, Drake C, Eeles R, Kellokumpu-Lehtinen P, Kantoff P, James N, Higano C, Heidenreich A, Halabi S, Gleave M, Frydenberg M, Fizazi K, Feng F, Fanti S, Evans C, Efstathiou E, Gillessen Sommer S. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *Eur Urol* 2017

Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. *ESMO Open* 2017; 2:e000172.

Keizman D, Daugaard G, Gillessen Sommer S, Mortensen J, Rouvinov K, Mermershtain W, Sarid D, Dresler H, Gottfried M, Cathomas R, Mueller J, Petersen P, Neiman V, Desax M, Rosenbaum E, Peer A, Reichegger H, Fosboel M, Omlin A. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases—analysis of an international multicenter database. *Prostate Cancer Prostatic Dis* 2017; 20:289–293.

Lorente D, Hall E, IJzerman M, Terstappen L, Payne H, Mateo J, Perez R, Tunariu N, Bianchini D, Porta N, Kolinsky M, Rescigno P, Miranda M, Gilman A, Omlin A, Pezaro C, Mehra N, Ravi P, de Bono J. Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. *Eur Urol Focus* 2016; 4:235–244.

Lorente D, Crespo M, Flohr P, Mateo J, Altavilla A, Ferraldeschi R, Bianchini D, Attard G, Tunariu N, Miranda S, Riisnaes R, Omlin A, Zafeiriou Z, Nava-Rodrigues D, Pérez-López R, Pezaro C, Mehra N, Sheridan E, Figueiredo I, de Bono J. Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. *Clin Genitourin Cancer* 2016; 14:485–493.

Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol* 2016

Gillessen Sommer S, Omlin A, Hager S. Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature review. *Annals of Oncology* 2016; 27:975–984.

Pérez-López R, Koh D, de Bono J, Leach M, Zivi A, Omlin A, Bianchini D, Mateo J, Collins D, Blackledge M, Lorente D, Tunariu N. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. *Radiology* 2016; 280:151–60.

Cathomas R, Wyler S, Wild P, Thalmann G, Stenner F, Schäfer N, Rentsch C, Müntener M, Jichlinski P, Iselin C, Gillessen Sommer S, Eberli D, Berthold D, Amram M, Aebersold D, Schmid H, Omlin A. Medikamentöse Behandlung des metastasierten Prostatakarzinoms. *Schweiz Med Forum* 2016; 16:266–72.

Gillessen Sommer S, Fanti S, Omlin A, panelists and authors of APCCC. Reply to the letter to the editor 'Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015' by Gillessen et al. *Ann Oncol* 2015; 26:2354–5.

Schmid S, Omlin A, Blum D, Strasser F, Gillessen Sommer S, Rothermundt C. Assessment of Anticancer-Treatment Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer - Going beyond PSA and Imaging, a Systematic Literature Review. *Ann Oncol* 2015

Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol* 2015; 26:1589–604.

Desax M, Hundesberger T, Rothermundt C, Omlin A, Gillessen Sommer S. Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases. *Clin Genitourin Cancer* 2015; 13:e385–6.

Omlin A, Sartor O, Rothermundt C, Cathomas R, de Bono J, Shen L, Su Z, Gillessen Sommer S. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. *Clin Genitourin Cancer* 2015

Pezaro C, Sohaib A, de Bono J, Dearnaley D, Parker C, Lorente D, Bianchini D, Attard G, Mukherji D, Perez-Lopez R, Omlin A, Tunariu N. Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. *Clin Radiol* 2014

Ferraldeschi R, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, Altavilla A, Mateo J, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, de Bono J. PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. *Eur Urol* 2014

Lorente D, de Bono J, Gillessen Sommer S, Dearnaley D, Parker C, Tunariu N, Zafeirou Z, Altavilla A, Mateo J, Perez R, Pezaro C, Ferraldeschi R, Omlin A, Attard G. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. *Br J Cancer* 2014

Weisshaupt C, Hitz F, Albrich W, Omlin A. Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading. *BMJ Case Rep* 2014; 2014

Carreira S, Demichelis F, S de Bono J, Tunariu N, Flohr P, Rodrigues D, Omlin A, Pezaro C, Frenel J, Lorente D, Prandi D, Miranda S, Ferraldeschi R, Grist E, Goodall J, Romanel A, Attard G. Tumor clone dynamics in lethal prostate cancer. *Sci Transl Med* 2014; 6:254ra125.

Blagden S, Spicer J, Twelves C, Jones K, Prince J, Inatani M, Shiokawa R, Noguchi K, Pope L, Riisnaes R, Swales K, Decordova S, Anthoney A, Pinato D, Zivi A, Stavrou C, Josephs D, Omlin A, Banerji U. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. *Clin Cancer Res* 2014; 20:5908-17.

Mukherji D, Omlin A, Pezaro C, Shamseddine A, de Bono J. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. *Cancer Metastasis Rev* 2014; 33:555-66.

Templeton A, Tannock I, de Bono J, Attard G, Vera-Badillo F, Leibowitz-Amit R, McNamara M, Omlin A, Pezaro C, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. *Cancer* 2014; 120:3346-52.

Yap T, Lorente D, Omlin A, Olmos D, de Bono J. Circulating tumor cells: a multifunctional biomarker. *Clin Cancer Res* 2014; 20:2553-68.

Loriot Y, Ouatas T, Holtkamp G, Baron B, Heeringa M, Baskin-Bey E, James N, Omlin A, Molife R, Van den Brande J, Jones R, Fizazi K, de Bono J. Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. *Invest New Drugs* 2014; 32:995-1004.

Blum D, Strasser F, Kaasa S, Hayoz S, Dewolf-Linder S, Mingrone W, von Moos R, Walker J, Omlin A, Koeberle D, Ribi K. Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice. *Support Care Cancer* 2014; 22:2425-34.

Hundsberger T, Omlin A, Hägele-Link S, Vehoff J, Strasser F. Autonomic Dysfunction in Cancer Cachexia Coincides With Large Fiber Polyneuropathy. *J Pain Symptom Manage* 2014; 48:611-618.

Schmid S, Fornaro J, Rothermundt C, Omlin A, Brändle M, Rupp N, Gillessen Sommer S. Abiraterone--what is wrong with the adrenal glands?. *Clin Genitourin Cancer* 2014; 12:e133-7.

Molife L, Pelling K, Temple G, Heath C, Wheatley D, Oommen N, Thompson E, Jenkins P, Hickish T, Pedley I, O'Sullivan J, Olmos D, Fong P, Lumsden G, Bloomfield D, Karavasilis V, Jones R, Omlin A, de Bono J. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. *Future Oncol* 2014; 10:219-31.

Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. *Ther Adv Urol* 2014; 6:3-14.

Leibowitz-Amit R, de Bono J, Tannock I, Sridhar S, Knox J, Attard G, Seah J, Vera-Badillo F, Keizman D, Atenafu E, Pezaro C, Omlin A, Templeton A, Joshua A. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. *Ann Oncol* 2014; 25:657-62.

Lorente D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin A, Rodriguez-Vida A, Bianchini D, de Bono J. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. *Eur J Cancer* 2014; 50:1042-3.

Omlin A, Stienen M, Brügge D, Fretz C, Gillessen Sommer S, Hundsberger T. Maligne spinale Kompression - Prävention, Erkennung und «State of the Art»-Behandlung. *SMF* 2014; 14:820-825.

Pezaro C, de Bono J, Parker C, Dearnaley D, Bianchini D, Ferraldeschi R, Lorente D, Altavilla A, Omlin A, Attard G. Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. *Eur Urol* 2013

Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'. *Br J Cancer* 2013; 110:267-8.

Renz M, Mao S, Omlin A, Büche D, Cerny T, Strasser F. Spiritual Experiences of Transcendence in Patients With Advanced Cancer. *Am J Hosp Palliat Care* 2013

Pezaro C, de Bono J, Tunariu N, Crespo M, Altavilla A, Riisnaes R, Mukherji D, Bianchini D, Ferraldeschi R, Nava Rodrigues D, Lorente D, Omlin A, Attard G. Visceral Disease in Castration-resistant Prostate Cancer. *Eur Urol* 2013; 65:270-3.

Bianchini D, de Bono J, Scher H, Attard G, Rathkopf D, Buchbinder A, Zivi A, Riisnaes R, Miranda S, Figueiredo I, Crespo M, Mukherji D, Ferraldeschi R, Lorente D, Pezaro C, Omlin A, Danila D. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. *Br J Cancer* 2013; 109:2579-86.

Bianchini D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin A, Rodriguez-Vida A, Lorente D, de Bono J. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. *Eur J Cancer* 2013; 50:78-84.

Pezaro C, Omlin A, Lorente D, de Bono J. Management of patients with castration-resistant disease. *Hematol Oncol Clin North Am* 2013; 27:1243-60, ix.

Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. *Br J Cancer* 2013; 109:1079-84.

Sandhu S, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter C, Iannone R, Kaye S, de Bono J, Thway K, Kreischer N, Schelman W, Wilding G, Moreno V, Baird R, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Wenham R. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. *Lancet Oncol* 2013; 14:882-92.

Pezaro C, de Bono J, Olmos D, Reid A, Seed G, Bianchini D, Omlin A, Cassidy A, Tunariu N, Mukherji D, Attard G. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. *Br J Cancer* 2013; 109:325-31.

Sandhu S, Assiotis I, Olmos D, Yap T, Fong P, Tunariu N, Koh D, Molife L, Kaye S, Lord C, Ashworth A, Fenwick K, Campbell J, Omlin A, Hylands L, Miranda S, Barber L, Riisnaes R, Reid A, Attard G, Chen L, Kozarewa I, Gevensleben H, de Bono J. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. *Ann Oncol* 2013; 24:1416-8.

Yap T, Omlin A, de Bono J. Development of therapeutic combinations targeting major cancer signaling pathways. *J Clin Oncol* 2013; 31:1592-605.

Omlin A, Blum D, Wierecky J, Haile S, Ottery F, Strasser F. Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study. *J Cachexia Sarcopenia Muscle* 2013; 4:55-61.

Laurent J, Gnad-Vogt U, Stupp R, Quarantino S, Sessa C, Omlin A, Beck J, Gallerani E, Liedert B, Ongarello S, Bertrand C, Vicari M, Joffraud M, Gillessen Sommer S, Touvrey C, Speiser D. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. *J Transl Med* 2013; 11:5.

Omlin A, Attard G, Parker C, Thompson E, Maier G, Ferraldeschi R, Olmos D, Bianchini D, Sandhu S, Mulick Cassidy A, Mukherji D, Pezaro C, de Bono J. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. *Eur Urol* 2013; 64:300-6.

Oberholzer R, Hopkinson J, Baumann K, Omlin A, Kaasa S, Fearon K, Strasser F. Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. *J Pain Symptom Manage* 2012; 46:77-95.

Gillessen S, Speiser D, Laurent J, Kramer D, Liedert B, Mattiacci M, Omlin A, Sessa C, Beck J, Gallerani E, Gnad-Vogt U, Stupp R. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. *Eur J Cancer* 2012; 49:35-44.

Omlin A, de Bono J. Therapeutic options for advanced prostate cancer: 2011 update. *Curr Urol Rep* 2012; 13:170-8.

Omlin A, Gillessen Sommer S. [Inhibitors of androgen and estrogen biosynthesis in castration-resistant prostate cancer]. *Urologe A* 2012; 51:8-14.

Hitz F, Klingbiel D, Omlin A, Riniker S, Zerz A, Cerny T. Antithrombotic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial. *Ann Hematol* 2011; 91:613-20.

Yap T, Zivi A, Omlin A, de Bono J. The changing therapeutic landscape of castration-resistant prostate cancer. *Nat Rev Clin Oncol* 2011; 8:597-610.

Blum D, Strasser F, Fearon K, Kaasa S, Stone P, Tan B, Solheim T, Baracos V, Omlin A, European Palliative Care Research Collaborative. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. *Crit Rev Oncol Hematol* 2011; 80:114-44.

Omlin A, Kaelin M, Templeton A, Jungi M, Gillessen Sommer S, Graf H, Rothermundt C. Metastasiertes Prostatakarzinom – Behandlungsmöglichkeiten nach der Hormontherapie. *Swiss Medical Forum* 2010; 10:483-485.

Blum D, Omlin A, Fearon K, Baracos V, Radbruch L, Kaasa S, Strasser F, European Palliative Care Research Collaborative. Evolving classification systems for cancer cachexia: ready for clinical practice?. *Support Care Cancer* 2010; 18:273-9.

Jörger M, Omlin A, Cerny T, Früh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. *Current drug targets* 2010; 11:37-47.

Omlin A, D'Addario G, Gillessen Sommer S, Cerny T, Vonhessling A, Früh M. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. *Lung cancer (Amsterdam, Netherlands)* 2009; 65:383-4.

Rothermundt C, Omlin A, Gillessen Sommer S. 'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2009; 20:1144-6.

Blum D, Omlin A, Strasser F. Gewichts- und Appetitverlust bei Krebspatienten. *The Medical Journal* 2009 2009; 3:27-29.

Spirig C, Omlin A, D'Addario G, Loske K, Esenwein P, Geismar J, Ruhstaller T. Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report. *J Med Case Reports* 2009; 3:93.

Templeton A, Omlin A, Strasser F. An update on the pharmacological management of the cancer anorexia-cachexia-syndrome. *European Journal of Palliative Care* 2007; 14:186-190.

Omlin A, Goldberg H, Scandolaro L, Gastelblum P, Ozsahin M, Dohr D, Christie D, Oppitz U, Abacioglu U, Morgan D, Gutierrez Miguelez C, Amichetti M, Azria D, Cole B, Fournieret P, Poortmans P, Naehrig D, Miller R, Krengli M, Gruber G. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. *The lancet oncology* 2006; 7:652-6.

Omlin A, Mühlemann K, Fey M, Pabst T. Pneumococcal vaccination in splenectomised cancer patients. *European journal of cancer (Oxford, England : 1990)* 2005; 41:1731-4.

Projekte (17)

A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS

Klinische Forschung - 17.07.2020 - 17.07.2022

Automatisch geschlossen

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic HormoneSensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Klinische Forschung - 03.03.2020 - 10.03.2030

Geplant

SAKK 01/18 Reduced intensity radio-chemotherapy for satge IIA/B seminoma. A multicenter, open label phase II trial with 2 cohorts

Klinische Forschung - 24.07.2019 - 24.07.2030

Laufend

Peace-4

Klinische Forschung - 26.04.2019 - 06.05.2027

Geplant

Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199) / MK-3475-199 Pembro Prostata

Klinische Forschung - 27.07.2016 - 30.06.2019

Automatisch geschlossen

An Open Label Biomarker Driven Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior Response to AA (Abi-RE)

Klinische Forschung - 12.06.2016 - 31.12.2017

Automatisch geschlossen

Single arm open label phase II pilot study of carboplatin in patients with metastatic castration-resistant prostate cancer (CRPC) and PTEN-loss and/or DNA repair defects. PRO-PLAT

Klinische Forschung - 17.02.2016 - 01.01.2019

Automatisch geschlossen

An open-label, multicohort, phase II study of MPDL3280A in advanced solid tumors

Klinische Forschung - 08.07.2015 - 31.07.2019

Automatisch geschlossen

A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280A (ANTI-PD-L1 ANTIBODY) compared with chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after failure with platinum-containing chemotherapy. GO29294

Klinische Forschung - 02.04.2015 - 01.12.2016

Automatisch geschlossen

SINGLE ARM OPEN LABEL PHASE II PILOT STUDY OF CARBOPLATIN

Klinische Forschung - 02.12.2014 - 31.12.2017

Automatisch geschlossen

MP0250; A phase I multi-centre, open-label, repeated-dose, dose-escalation study to assess safety, tolerability and pharmacokinetics of MP0250 in patients with advanced solid tumours

Klinische Forschung - 23.10.2014 - 30.09.2016

Automatisch geschlossen

SAKK 63/12 Prospective cohort study with collection of clinical data and serum of patients with prostate disease

Klinische Forschung - 15.10.2014 - 15.10.2024

Laufend

Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)

Klinische Forschung - 07.07.2014 - 31.12.2026

Automatisch geschlossen

LDE225 in combination with Paclitaxel in patients with advanced solid tumors. A multicenter phase I trial

Klinische Forschung - 30.10.2013 - 01.10.2015

Automatisch geschlossen

Swiss Austrian German Testicular Cancer Cohort Study – SAG TCCS

Klinische Forschung - 03.10.2013 - 31.12.2026

Laufend

Entwicklung von Dienstleistungsmodellen der integrierten Onkologie und Palliative Care: Untersuchung von temporalen Aspekten, Involvierung von Onkologen, und Chemotherapie-Gebrauch

Klinische Forschung - 10.11.2010 - 31.10.2011

Abgeschlossen

The European Palliative Care Research Collaborative. Improved treatment of pain, depression and fatigue through translation research

Klinische Forschung - 01.11.2006 - 31.10.2010

Abgeschlossen

Kantonsspital St.Gallen
Rorschacher Strasse 95
CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch